Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of the GamTBvac Recombinant Subunit Tuberculosis Vaccine for the Prevention of Non-HIV-associated Pulmonary Tuberculosis in Volunteers Aged 18 Years and Older.
NCT04975737 is registered in ClinicalTrials.gov with Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of the GamTBvac Recombinant Subunit Tuberculosis Vaccine for the Prevention of Non-HIV-associated Pulmonary Tuberculosis in Volunteers Aged 18 Years and Older.
- Lead sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- January 20, 2022
- Completion date
- December 31, 2026
- Enrollment
- 9,500 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.